Alle afleveringen

462 afleveringen, van nieuw naar oud

#413 ‒ The neuroscience of emotion: challenging conventional theories of emotion, how the brain predicts and constructs our experiences, and gaining greater control over how we feel | Lisa Feldman Barrett, Ph.D.

26 oktober 2026 · 2 uur 34 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter sits down with Dr. Lisa Feldman Barrett, a psychologist, neuroscientist, author, and distinguished professor at Northeastern University whose research challenges many of the conventional assumptions about emotions and how the brain works. Lisa is best known for her theory of constructed emotion, which challenges the idea that emotions such as fear, anger, and sadness are hardwired responses with universal biological signatures. She begins by explaining how unexpected findings early in her research led her to question traditional theories of emotion. She discusses why studying individual variation, rather than relying on averages, is essential to understanding the brain. Lisa then explores the idea that the brain is fundamentally a predictive system rather than a reactive one. She explains how past experiences and memories shape what we perceive, feel, and do. She also describes how the brain continuously anticipates and regulates metabolism through a process called allostasis. The conversation then turns to the effects of chronic stress, uncertainty, and childhood adversity on physical and emotional health. Lisa explains how our relationships help regulate our nervous systems and why the loss of a loved one can have such a profound physiological impact. She also discusses how deliberate practice and new experiences can reshape the brain's predictions, potentially changing how we think, feel, and respond to the world around us. Throughout the discussion, Peter and Lisa explore how this framework challenges traditional views of emotion and offers a greater sense of agency over our emotional lives.

We discuss:

How unexpected results in graduate school changed Lisa's understanding of emotion [3:30];

Why variation is the norm for emotion, and the danger in tracking averages instead of characterizing variation [1…
#412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | Siddhartha Mukherjee, M.D., Ph.D.

19 oktober 2026 · 2 uur 4 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter welcomes back Dr. Siddhartha Mukherjee, a physician, oncologist, researcher, and the Pulitzer Prize-winning author of The Emperor of All Maladies. Fifteen years after the book was first published, Sid released an updated edition. This conversation examines what has changed in our understanding of cancer—not only in how we treat it, but in how we think about its causes, prevention, detection, and biology. Sid explores the contributions of genetics, environmental exposures, random mutations, and inflammation to cancer risk, including the emerging role of hyperinsulinemia and metabolism. He discusses why detecting cancer early remains so difficult, particularly in pancreatic cancer, and how advances in immunotherapy, CAR T cell therapy, and targeted treatments such as KRAS inhibitors are changing the treatment landscape. The conversation then broadens beyond cancer to what Sid calls "regenerative failure"—the declining ability of tissues to repair and replenish themselves with age. Peter and Sid explore how this process may contribute to conditions such as osteoarthritis, and whether longevity should be approached less as the prevention of individual diseases and more as the preservation of regenerative capacity. Sid weighs in on the potential for chemoprevention, metabolic interventions, and AI to transform cancer prevention and treatment. Finally, they discuss what it would take to develop meaningful biomarkers of longevity that could ultimately help to extend human healthspan and lifespan.

We discuss:

What oncology has learned in the 15 years since The Emperor of All Maladies was published [2:45];

The contributions of genetic risk, bad luck, and inflammation to cancer [14:45];

The role of metabolism and hyperinsulinemia in cancer [31:00];

Osteoarthritis: the role of inflammation and regenerative stem cell…
#411 ‒ AMA #90: Strong convictions, loosely held: how Peter's views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed

12 oktober 2026 · 18 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter looks back on 400 episodes of The Drive with another installment of "strong convictions, loosely held," revisiting some of the positions he has taken over more than eight years of the podcast. He explains why changing one's mind in response to new evidence, conversations with experts, and clinical experience is essential for practicing medicine well. Peter begins with nutrition, describing how his views on ketogenic diets, extended fasting, and the framework of dietary restriction, time restriction, and calorie restriction have evolved. He explains why he no longer takes metformin for longevity and discusses his growing uncertainty around rapamycin despite compelling animal data. Peter also revisits his views on cancer screening, including whole-body MRI and liquid biopsies for early detection. On exercise, Peter explains how his approach to cardiorespiratory training and the 80/20 Zone 2 framework has changed, particularly for people with limited time to train. He also shares why he has moved away from heavy barbell squats and deadlifts and how he now thinks about balancing benefit and injury risk. Throughout the episode, Peter emphasizes the importance of focusing on durable principles, strong foundations, and sustainable practices rather than chasing optimizations that provide marginal gains.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #90 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Strong convictions, loosely held: changing opinions as evidence, expert conversations, and clinical experience evolve [2:00];

Nutrition: Peter's evo…
#410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.

5 oktober 2026 · 1 uur 58 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter sits down with Dr. Kathryn (Katie) Gray, a physician-scientist, high-risk obstetrician, and maternal-fetal medicine specialist at the University of Washington School of Medicine. Katie begins by explaining the remarkable physiologic changes that occur during pregnancy and how the cardiovascular, metabolic, and hormonal systems adapt to support both mother and developing fetus. From there, the conversation turns to some of the most important complications that can arise. Katie explains how gestational diabetes is screened for and treated, and what a diagnosis may mean for the long-term health of both mother and child. She then walks through the biology of preeclampsia, including who is at risk and how the condition is managed. She also discusses HELLP syndrome and postpartum depression. Peter and Katie explore the realities of labor and delivery, including breech presentation, the role of midwives, and the trade-offs between vaginal and cesarean delivery. The conversation also covers stillbirth and the growing role of cell-free DNA in prenatal genetic screening. Other topics include prenatal nutrition and folate, breastfeeding, and exercise during pregnancy. Throughout the episode, Peter and Katie return to a larger question: What can pregnancy reveal about a woman's long-term health? They discuss how complications during pregnancy can provide important clues about future health risks. Finally, Katie highlights some of the major questions that remain unanswered in maternal health and why greater investment in research is needed to improve outcomes for mothers and their children.

Disclaimer: The views expressed on this podcast are solely those of Dr. Kathryn Gray and do not represent the University of Washington or any of its affiliated units. Dr. Gray speaks solely in a personal capacity, and nothing here shou…
#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

28 september 2026 · 2 uur 26 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Lloyd B. Klickstein is a physician-scientist who has spent more than 20 years at the intersection of drug discovery, healthy aging, and preventive medicine. Drawing on his experience in academic medicine, translational research, and biotechnology, Lloyd walks through the full arc of modern drug development. He explains how scientists identify an unmet medical need and decide which diseases and therapeutic targets are worth pursuing. From there, he takes us through the process of engineering a drug, testing it in animals, and navigating clinical trials and regulatory approval. Using bimagrumab as a case study, Lloyd explains the rationale for targeting myostatin and activin signaling to increase muscle mass and strength and describes how the antibody was engineered and screened. He then walks through what was learned from early clinical trials. Unexpected effects on fat mass and type 2 diabetes helped reshape bimagrumab's development as a potential treatment for obesity, including its use in combination with semaglutide. Along the way, Peter and Lloyd explore the differences among drug modalities, including biologics and small-molecule therapeutics. They discuss the roles of patents and capital allocation in drug development, along with the requirements for IND submission and GMP manufacturing. They also examine why developing a new drug takes so long and costs so much, and why identifying failures early is critical. At the end of the episode, the conversation turns to mTOR inhibition and geroprotection, as well as Lloyd's current work on a novel pharmacologic approach to cancer prevention. This episode provides a rare behind-the-scenes look at how new medicines are actually created and the scientific, regulatory, and economic decisions that determine which ideas ultimately make it to patients.

We discuss:

Lloyd's path from academi…
#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

21 september 2026 · 16 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into thyroid health and explains why diagnosing and managing thyroid dysfunction is unusually complex. He begins with the basic biology of the thyroid gland and three commonly measured hormones—free T4, free T3, and TSH. He explains how T4 is converted to the active hormone T3 and the important functions T3 performs throughout the body. He also explains what reverse T3 is and when it may be useful to measure it. Peter then breaks down thyroid blood tests and their limitations and provides a practical framework for evaluating suspected thyroid dysfunction. He explains why symptoms alone are insufficient for diagnosis and reviews the criteria for diagnosing hypothyroidism, along with conditions that can mimic it. He also explores how hypothyroidism can be both underdiagnosed and overtreated and how to navigate subclinical hypothyroidism. Peter discusses treatment with T4 and T3, including why some patients continue to experience symptoms despite standard T4 replacement. He also explains how thyroid medications should be taken to optimize absorption. Additional topics include Hashimoto's disease, thyroid considerations during pregnancy, hyperthyroidism, the risks of excess iodine, and supplements marketed to support thyroid function. Finally, Peter offers guidance for patients who continue to feel unwell despite apparently normal thyroid tests.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #89 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Why thyroid management is unusually complex and what the thyroid does [2:00];

Why s…
#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

14 september 2026 · 1 uur 59 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data. Finally, Peter and Michael explore the benefits of omega-3 fatty acids and the challenge of delivering DHA to the brain, as well as ongoing work on klotho in preparation for clinical trials. They discuss the potential for AI to transform clinical trials and the scientific and financial challenges of developing new therapies for cardiovascular and neurodegenerative disease.

We discuss:

Michael's path to lipidology, and his passion for primary prevention [3:30];

Reframing prevention around causal drivers rather than time horizon [9:30];

What CETP inhibition does, the evolutionary biology of CETP, the HDL-raising rationale, and Pf…
Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

7 september 2026 · 1 uur 17 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter delves into the critical subject of blood pressure, which is one of the three primary causes of atherosclerosis, along with high apoB and smoking. He begins by unraveling the nature of high blood pressure, its prevalence, and why it often goes undiagnosed. Peter describes in detail the proper way to accurately measure blood pressure and what determines a diagnosis. Next, Peter discusses the actionable steps one can take in response to high blood pressure, shedding light on the extent to which factors like weight loss, exercise, and nutrition can make an impact. He also explores the pharmacological options available and offers valuable insights on how to approach them.

We discuss:

Blood pressure and other risk factors for cardiovascular disease [2:30];

Defining blood pressure and the purpose and meaning of a blood pressure measurement [5:45];

The implications of high blood pressure and the importance of maintaining an optimal level [10:30];

The importance of accurate measurements of blood pressure and how Peter approaches the care of patients at the very top range of "normal" [21:45];

The prevalence of high blood pressure—a hidden epidemic? [24:30];

The consequences of high blood pressure on cardiovascular health, brain health, kidneys, and more [24:45];

Low blood pressure: symptoms and consequences [35:30];

How to properly measure blood pressure [37:45];

Daily variance in blood pressure and the transient changes in blood pressure during exercise [48:00];

Primary hypertension vs. secondary hypertension: what to look for [51:45];

Lifestyle factors impacting blood pressure: weight loss, exercise, and sodium [57:45];

Impact of insulin resistance and type 2 diabetes on blood pressure [1:04:45];

How sleep impacts blood pressure [1:06:45];

Pharmacologic options for managing bloo…
#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

31 augustus 2026 · 1 uur 56 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Brian Grosberg is a world-renowned headache specialist who joins Peter to provide a master class on the diagnosis and treatment of headache disorders. In this episode, Brian explains the distinction between primary and secondary headaches and breaks down the defining features of the "big three" primary headache types (migraine, cluster, and tension headache)—highlighting how often they are misdiagnosed and how they are treated. He explores the epidemiology of headaches, describing migraine as an invisible disease affecting about 12% of the population, disproportionately affecting women, while cluster headaches more often affect men. He discusses the major gap between demand for headache care and available specialists, and he offers advice on when to see a physician. Brian dives into the multifactorial nature and pathophysiology of migraine, including genetic and hormonal influences, neurovascular changes, and inflammatory signaling, and connects these mechanisms to modern therapies. Throughout the conversation, he emphasizes the individualized nature of headache disorders and the importance of a detailed headache diary. Brian shares practical strategies for treating headaches including lifestyle changes, medications, and neuromodulation devices.

We discuss:

Brian's interest in headaches and how Peter met Brian [2:15];

Differentiating the types of headaches: primary versus secondary headache and tension versus migraine headache [7:30];

The epidemiology and burden of migraine, its disproportionate affect on women, and the shortage of headache specialists [20:00];

Genetic susceptibility to migraine and the role of hormones [24:45];

Migraine triggers, the impact of hormones, and the importance of a headache diary [31:15];

The phases of a migraine: premonitory symptoms, aura, the headache itself, and the postdrome [38:15];

Tensio…
#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

24 augustus 2026 · 39 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can provide false reassurance, which labs he uses to assess liver health, and the tools available for detecting fibrosis and more advanced disease. Peter then breaks down the interventions that can meaningfully improve liver health once risk or disease is identified, ranging from diet and exercise to GLP-1–based therapies and other medications. Finally, he examines popular claims around liver "detoxification" and supplements, separating what is supported by evidence from what is unlikely to meaningfully improve liver health.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #88 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Why the liver is the "canary in the coal mine" for metabolic dysfunction, and an overview of what the liver does [2:00];

The relationship between the liver and blood sugar control [6:30];

A framework for understanding how metabolic disease affects the liver [9:15];

Chronic caloric surplus and insulin resistance as drivers of liver disease [11:00];

Liver diseases that result from met…
#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

17 augustus 2026 · 2 uur 18 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness.

We discuss:

Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45];

A short primer on the different classes of drugs used in psychiatry [12:45];

Evaluation of a patient with bipolar disorder [26:00];

An evolutionary perspective on depression [33:30];

Changes in the modern world triggering mental heal…
#403 ‒ Peptides: separating scientific promise from marketing hype

10 augustus 2026 · 53 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.

We discuss:

What peptides are and why they must be evaluated individually [3:15];

A five-question framework for evaluating peptides and other drugs [5:30];

A three-tier system for classifying the scientific evidence behind peptides [10:00];

Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00];

Why BPC-157's expanding claims do not indicate a broad mechanism [20:45];

CJC-1295: biological activity versus meaningful clinical benefit [23:30];

Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30];

The placebo effect, and the importance of controlled trials for evaluating peptides [31:00];

What FDA approval provides when evaluating peptide safety and effectiveness [34:45];

Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30];

Approved peptides sold on the gray market: why evidence for an appro…
#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.

3 augustus 2026 · 2 uur 25 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test.

We discuss:

How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30];

How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15];

How NMR spectroscopy measures lipoprotein particle size and concentration [20:30];

Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45];

Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30];

How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for…
#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

27 juli 2026 · 1 uur 4 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies.

We discuss:

The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30];

Why basic research and nature's biological innovations are the foundation of medical progress [10:45];

The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15];

From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00];

From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00];

The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15];

The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30];

Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and

More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube
#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks

20 juli 2026 · 20 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Defining environmental pollution and its role in longevity [1:45];

Why the topic of environmental pollution is both polarizing and difficult to study [6:00];

Where environmental exposures fit within the hierarchy of health priorities, and a framework for evaluating which environmental risks are worth addressing [13:15];

Understanding air pollution: the major pollutants and why PM2.5 is a key marker of health risk [16:00];

Indoor air pollution: why indoor air quality often matters most for reducing personal …
#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

13 juli 2026 · 1 uur 57 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care.

We discuss:

Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45];

How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15];

The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30];

Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45];

Why forgetting names is usually normal and when word-finding problems become concerning [29:00];

Why women are at higher risk for Alzheimer's disease and how menopause influences co…
Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

6 juli 2026 · 1 uur 44 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably.

We discuss:

Peter's humorous experience talking nutrition with a second grader [3:00];

Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30];

Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45];

The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00];

Grip strength as a simple yet powerful predictor of all-cause mortality [17:15];

Is muscle strength causal or just a marker of health? [20:30];

Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00];

How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15];

How muscle mass and strength decline with age, and …
#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

29 juni 2026 · 10 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45];

Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45];

How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15];

Comparing lean mass loss across semaglutide, tirzepa…
#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

22 juni 2026 · 1 uur 59 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

View our full terms of use

Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility.

Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka; Website: Renato Tomioka, M.D., Ph.D.

We discuss:

0:00:00 - Intro

0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development

0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms

0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health

0:18:52 - Recognizing endometriosis and adenomyosis: the "6 Ds" of endometriosis and key differences in clinical presentation

0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location…
#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

15 juni 2026 · 50 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment.

We discuss:

Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45];

Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30];

A framework for personalizing screening [8:45];

Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30];

Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45];

Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00];

MRI for high-risk women: the benefits of supplemental s…
#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

8 juni 2026 · 1 uur 41 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation.

We discuss:

The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45];

How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45];

How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00];

How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00];

How apoB structure influences LDL receptor binding and LDL clearance [39:00];

How neurons acquire choles…
#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

1 juni 2026 · 55 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep.

We discuss:

The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00];

Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15];

Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45];

The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00];

Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45];

Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, a…
#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

25 mei 2026 · 13 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #85 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

How to properly define health problems before considering medications or supplements [1:45];

How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00];

Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as cli…
#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results

18 mei 2026 · 1 uur 2 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight.

We discuss:

Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45];

The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15];

The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30];

Questions to ask when considering genetic testing [15:45];

Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00];

Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45];

Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00];

Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45];

Functional medicine genetic testing: the gap between biological plausib…
#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy

11 mei 2026 · 8 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age.

We discuss:

CRC statistics and goals for this episode [1:00];

Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00];

Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30];

Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15];

Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15];

Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45];

Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00];

Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30];

Non-invasive screening options for CRC: benefits, limitations, and t…
#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration

4 mei 2026 · 9 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Topics overview [1:15];

Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];

Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];

Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];

Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];

Whether someone can be overweight ye…
#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit

27 april 2026 · 54 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers.

We discuss:

Topics to be covered and goals for this episode [2:00];

Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45];

How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00];

Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30];

Systems and tools designed to correct human bias [18:15];

How to think scientifically pt. 1: Notice when you're feeling certain [20:30];

How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00];

How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15];

How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45];

How to think scientifically pt. 5: Outsource your thinking carefully [36:15];

Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15];

Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00];

The key principles of scientific thinking, and a practical frame…
#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

20 april 2026 · 46 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.

We discuss:

The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];

PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];

The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];

How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];

Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];

Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];

Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to arg…
#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

13 april 2026 · 22 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15];

What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30];

A framework for evaluating peptides: …
#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

6 april 2026 · 56 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes.

We discuss:

Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00];

How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00];

The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45];

The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45];

Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15];

The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00];

The DO-HEALTH study results: findings, takeaways, and open questions [27:45];

The DunedinPACNI study: how the model was developed and what it may add to the field [35:00];

The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes […
#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

23 maart 2026 · 19 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance [1:30];

How health priorities and training strategies should evolve from early adulthood through older age [2:45];

Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00];

Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00];

How to use wearable data effectiv…
#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

16 maart 2026 · 53 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients.

We discuss:

Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15];

CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15];

The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45];

The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30];

Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30];

The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00];

Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer's disease [30:45];

Findings from the substudy of the BROA…
#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.

19 januari 2026 · 2 uur 8 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show's usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices.

We discuss:

The idea behind this episode, biases, and evidence-based thinking [5:15];

The four core arguments behind claims that seed oils are harmful [12:30];

The Minnesota Coronary Experiment (MCE) [14:30];

The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30];

Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00];

The Sydney Diet Heart Study (SDHS): an attempt to address the "duration problem" by enrolling a much higher-risk population [28:30];

Debating whether evidence from randomized trials supports…
#379 - AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence

12 januari 2026 · 39 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #79 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Rational for discussing cardiorespiratory fitness, zone 2, and VO₂ max despite having covered the topic extensively [2:30];

Why cardiorespiratory fitness and VO₂ max are powerful and modifiable predictors of all-cause mortality compared with other health metrics [7:30];

How age-related declines in VO₂ max constrain healthspan and everyday physical function [12:30];

The cardiorespiratory fitness triangle: how different training intensities contribute to building the aerobic base, the aerobic pe…
#378 ‒ Women's health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D.

5 januari 2026 · 2 uur 12 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Abbie Smith-Ryan is a leading researcher in exercise physiology whose work focuses on how training and nutrition influence body composition, metabolism, cardiovascular health, and women's health across the lifespan, with particular attention on perimenopause and post-menopause. In this episode, Abbie explains how early exercise and play help build the foundation for bone health, muscle development, and cardiorespiratory fitness in girls, as well as how puberty and menstruation shape athletic performance, motivation, and recovery. She also explores how women can tailor training and nutrition across the menstrual cycle through smart fueling, hydration, and inflammation management; examines the evidence behind supplements such as creatine, omega-3s, and magnesium; and unpacks the metabolic and body composition changes that accompany the transition into perimenopause and menopause. Finally, she covers practical exercise programming for busy women, training and nutrition considerations during pregnancy and postpartum, and the evolving role of hormone therapy alongside lifestyle-based, evidence-driven approaches that help women better advocate for their health.

We discuss:

Abbie's background in distance running and her interest in studying women's health around exercise [3:00];

The role of early-life exercise in building lifelong bone, muscle, and cardiovascular health in girls [4:00];

Training principles for premenstrual girls, the risks of early specialization and delayed puberty from intense training, and how youth sport participation can shape bone and spinal health [7:15];

Nutrition as fuel in young female athletes: supporting training, growth, and performance [11:00];

Training and recovery across the menstrual cycle: recovery, nutrition, supplements, and practical strategies for performance support [16:00];

The benefits of cr…
Building & Changing Habits | James Clear (#183 rebroadcast)

29 december 2025 · 2 uur 20 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

James Clear is the author of the New York Times bestseller Atomic Habits. His extensive research into human behavior has helped him identify key components of habit formation and develop the "Four Laws of Behavioral Change." In this episode, James provides insights into how both good and bad habits are formed, including the influence of genetics, environment, social circles, and more. He points to changes one can make to cultivate more perseverance and discipline and describes the profound impact habits can have when tying them into one's self-identity. Finally, James breaks down his "Four Laws of Behavioral Change" and how to use them to create new habits, undo bad habits, and make meaningful changes in one's life.

We discuss:

Why James became deeply interested in habits [1:45];

Viewing habits through an evolutionary lens [6:00];

The power of immediate feedback for behavior change, and why we tend to repeat bad habits [9:15];

The role of genetics and innate predispositions in determining one's work ethic and success in a given discipline [14:30];

How finding one's passion can cultivate perseverance and discipline [23:15];

Advantages of creating systems and not just setting goals [29:15];

The power of habits combined with self-identity to induce change [36:30];

How a big environmental change or life event can bring on radical behavioral change [50:30];

The influence of one's social environment on their habits [54:15];

How and why habits are formed [1:00:30];

How to make or break a habit with the "Four Laws of Behavior Change" [1:09:30];

Practical tips for successful behavioral change—the best strategies when starting out [1:16:15];

Self-forgiveness and getting back on track immediately after slipping up [1:30:30];

Law #1: Make it obvious—Strategies for identifying and creating cues to make and break habits [1:39:45];
…
#377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur Brooks

22 december 2025 · 1 uur 40 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this special episode of The Drive, Peter presents a curated "best of" conversation with bestselling author and previous guest Arthur Brooks, organized around four core themes: happiness itself, the forces that undermine it, the tools and practices that help cultivate it, and the courage required to live and love well. The episode brings together the most meaningful moments from two past interviews into a single, focused discussion that distills Brooks' most insightful ideas and offers practical takeaways for building a life that's both successful and deeply happy.

We discuss:

Happiness vs. happy feelings, and how happiness and unhappiness can coexist [2:15];

The six fundamental emotions [5:30];

The three main "macronutrients" of happiness [15:00];

Enjoyment: one of the three macronutrients of happiness [22:45];

Satisfaction: one of the three macronutrients of happiness [30:45];

Sense of purpose: one of the three macronutrients of happiness [38:45];

Fame: one of the traps that hijack our happiness [46:30];

Success addiction, workaholism, and their detriment to happiness [49:15];

The reverse bucket list: one of Arthur's tools and practices he recommends for moving past the traps that hijack our happiness [59:15];

Metacognition: one of Arthur's tools and practices he recommends for moving past the traps that hijack our happiness [1:01:00];

Taking charge of your happiness: discipline, transcendent experiences, and other deliberate actions for "happier-ness" [1:11:30];

Tracking happiness: the biomarkers and micronutrients behind the macronutrients of happiness [1:22:45];

The value of minimizing the self and looking outward [1:30:45];

How Arthur surprised himself with his ability to improve his happiness [1:34:45]; and

More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube
#376 - AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more

15 december 2025 · 22 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter tackles a wide-ranging set of listener questions spanning lifespan interventions, exercise, cardiovascular risk reduction, time-restricted eating, blood pressure management, hormone therapy, diagnostics, and more. Peter reveals the single most important lever for extending healthspan and lifespan, and explains how he motivates midlife patients using the Centenarian Decathlon framework. He discusses the importance of addressing high apoB and cholesterol even in metabolically healthy individuals with calcium scores of zero, how to manage high blood pressure, and how to accurately evaluate metabolic health beyond HbA1c. Additional topics include time-restricted eating, practical considerations around ultra-processed foods, nuanced approaches to HRT for women and TRT for men, and why early and expanded screening for chronic disease—colonoscopy, PSA, coronary imaging, low-dose CT—can be lifesaving. He also offers insights into treating prediabetes, crafting exercise programs for those short on time, and safely incorporating high-intensity training in older adults.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #78 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Introducing a wide-ranging AMA: practical perspectives on lifespan interventions, metabolic health, diet, hormones, diagnostics, and more [2:45];

Why exercise is the most powerful single intervention for lifespan and healthspan [4:15];

How Peter motivates midlife patients to prioritize exercise [6:00];

Why lifespan and healthspan should not be treated as competing priorities and how c…
#375 - Ketogenic diet, ketosis & hyperbaric oxygen: metabolic therapies for weight loss, cognition, Alzheimer's & more | Dom D'Agostino, Ph.D.

8 december 2025 · 2 uur 8 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Dom D'Agostino is a neuroscientist and professor at the forefront of metabolic therapies, including ketogenic diets, exogenous ketones, and hyperbaric oxygen. In this episode, Dom breaks down nutritional versus supplemental ketosis, defines meaningful ketone thresholds, and outlines practical ways to achieve ketosis. He explains how a ketogenic diet can support metabolic health and weight loss, and advises on how to maintain adequate protein and avoid common mistakes. Dom surveys the growing landscape of exogenous ketones—from salts and esters to 1,3-butanediol—and effective pairings like caffeine, MCT oil, and alpha-GPC. He highlights the role of ketogenic therapy in cancer (particularly glioblastoma) and its promise for neurodegenerative diseases. The conversation also covers recommended hyperbaric oxygen protocols for brain injuries and cognitive function, situations where fasting or ketones offer cognitive and anti-inflammatory benefits, and touches on the carnivore diet as a ketogenic variant with potential relevance for autoimmune and metabolic conditions.

We discuss:

Dom and Peter's shared interest in ketosis, and Dom's scientific journey [2:30];

Dom's work for the Navy on oxygen toxicity [7:00];

Nutritional ketosis defined: physiology, biomarkers, and how fasting and diet generate therapeutic ketones [15:00];

The historical roots of ketogenic diets in epilepsy treatment, and evidence showing ketones reduce seizure activity and strengthen brain resilience [19:00];

Dom's personal experience on the ketogenic diet: tracking macros, getting enough protein, and monitoring ketone levels [24:15];

Using a ketogenic diet for weight loss: Dom's guidance on protein, fiber, calorie tracking, lipid monitoring, and more [31:00];

Protein on ketogenic diets: Dom's rationale for higher intake and muscle preservation [38:00];

Incorpor…
#374 - The evolutionary biology of testosterone: how it shapes male development and sex-based behavioral differences, | Carole Hooven, Ph.D.

1 december 2025 · 2 uur 5 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Carole Hooven is a human evolutionary biologist whose research centers on testosterone, sex differences, and behavior. In this episode, she explores how prenatal testosterone orchestrates male development in the body and brain, how early hormonal surges shape lifelong behavioral tendencies, and what rare natural experiments—such as 5-alpha-reductase deficiency—reveal about the biology of sex differentiation. She discusses distinct male and female aggression styles through an evolutionary lens, how modern environments interact with ancient competitive drives, and the implications of attempting to suppress them. The conversation also covers testosterone across the lifespan, the role of hormone therapy in both men and women, and Carole's own experience after surgical menopause, culminating in a broader discussion of masculinity, cultural narratives, and the consequences of denying biological sex differences.

We discuss:

How Carole became interested in exploring the biological and evolutionary roots of sex differences and the role of testosterone [2:30];

How testosterone and other hormones influence sex differences in aggression and behavior across species [9:45];

How chromosomes, the SRY gene, and early hormones direct embryonic sexual differentiation [12:15];

A stark contrast of male social bonding compared to females, and evolutionary parallels in chimpanzees [19:30];

How hormones like DHT shape sexual differentiation, and how 5⍺-reductase deficiency reveals the distinct roles of these hormones [22:45];

How sex chromosomes and prenatal testosterone shape early brain development and explain sex differences in childhood behavior [31:30];

How gamete differences shape reproductive strategies, energetic costs, and sex-specific behavior [42:30];

How evolutionary biology shapes sex differences in play, aggression, and conflict reso…
The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast)

24 november 2025 · 1 uur 31 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Walter Green is a remarkable philanthropist, mentor, author of This Is the Moment!, and founder of the impactful "Say It Now" movement. In this episode, Walter delves into the unique insights gained from his challenging upbringing, discusses embracing mortality, and highlights the mindset of "finishing strong." He shares insights on intentionality, thinking in reverse, saying "no," prioritizing relationships, and the essence of focusing on others. The conversation focuses on the "Say It Now" movement, which stresses the importance of expressing sentiments to loved ones well before the end of life.

We discuss:

How Peter and Walter met through Ric Elias [3:30];

The unique perspectives and life lessons provided by Walter's challenging childhood [6:00];

Walter's harrowing experience with a sudden mental breakdown and his subsequent recovery with the help of therapy [12:15];

A diverse professional journey ending in great success [19:15];

The birth of a movement: celebrating friendships through public tributes and expressing gratitude to those who have shaped your life's journey [23:30];

Intentionality, thinking in reverse, saying "no", and other guiding principles for Walter [30:45];

Walter's global journey of gratitude on his 70th birthday, visiting friends, and creating memorable experiences [40:15];

The profound impact of acknowledging and expressing gratitude for the people who contribute to our lives [47:15];

The key elements for creating meaningful connections and cultivating deep, authentic friendships [53:15];

The "Say It Now" movement: the inspiration behind the remarkably impactful initiative [59:15];

What "finishing strong" means to Walter [1:08:15];

Finding peace at the end of life through expressing gratitude and finding purpose in serving others [1:16:45];

Resources to learn about "Say It Now" [1:27:00]; and

…
#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

17 november 2025 · 2 uur 20 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Antonio Bianco is a world-renowned physician-scientist and expert in thyroid physiology and metabolism. In this episode, Antonio explores the complex biology of thyroid hormone production, conversion, and regulation—highlighting how deiodinase enzymes modulate hormone activity at the tissue level and why that matters for interpreting lab results. He discusses the shortcomings of relying solely on TSH as a marker of thyroid function, the ongoing debate around combination therapy with T3 and T4 versus standard T4 treatment, and how genetics, tissue sensitivity, and individual variability influence thyroid hormone metabolism. The conversation also examines how hypothyroidism affects energy, mood, cognition, and longevity; why some patients remain symptomatic despite "normal" labs; and how future research could reshape treatment paradigms.

We discuss:

How the thyroid produces, stores, and activates hormones like T4 and T3 to finely regulate thyroid activity [2:45];

How fasting alters thyroid hormones to conserve energy [12:45];

Action of the deiodinases: how D1, D2, and D3 enzymes control the activation and inactivation of thyroid hormones [19:15];

The normal function of thyroid hormone and the roles of the hypothalamus, pituitary gland, and deiodinases in maintaining hormonal balance [23:30];

Why understanding thyroid physiology is essential for proper diagnosis and treatment of hypothyroidism [33:45];

Testing for thyroid hormones: understanding free vs. total levels, the limitations of current T3 assays, best practices, and more [36:00];

Genetic and sex-based variability in thyroid hormone regulation and their limited clinical significance [43:45];

Hyperthyroidism: causes, symptoms, diagnosis, and treatment options [46:00];

Hypothyroidism: diagnosis and autoimmune causes of hypothyroidism [56:30];

More on hypothyroidism: di…
#372 - AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications

10 november 2025 · 24 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter breaks down the science of dietary fiber, moving beyond the blanket advice to "eat more fiber" to uncover what it actually does in the body and where its benefits are truly supported by evidence. He explains how different types of fiber—soluble, insoluble, viscous, and fermentable—affect digestion, satiety, weight management, and glycemic control, and compares their impact to other, more potent metabolic tools. Peter also examines how certain fibers influence lipid metabolism and cardiovascular risk, evaluates the strength of evidence for fiber's role in colorectal cancer prevention, and highlights why some individuals may not tolerate specific fibers well. The discussion concludes with practical guidance on moving past generic fiber targets toward a more strategic and personalized approach that maximizes the true benefits of fiber.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #77 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Why it's time to re-examine the evidence behind dietary fiber recommendations [2:00];

Why it's hard to isolate fiber's true effects on health: the limits of nutritional epidemiology [5:45];

Defining dietary fiber: what it is, how it's digested, and why different types have different effects [8:15];

Understanding fiber properties: how solubility, viscosity, and fermentability shape its effects in the body [11:15];

Resistant starches explained: types, food sources, and how cooking and cooling influence their benefits [16:30];

A framework for evaluating each of the major health claims linked to fiber [19:15];

H…
#371 – Women's sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H.

3 november 2025 · 1 uur 52 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Sally Greenwald is an OB-GYN who specializes in women's sexual health from a hormonal and physiologic perspective, with expertise spanning desire, arousal, pelvic floor function, contraception, and menopause care. In this episode, she explains why sexual health is a vital component of overall well-being, exploring topics such as the drivers of desire, the anatomy of sexual function, myths and realities around orgasm, and the role of hormones in perimenopause and menopause. She also covers vaginal and pelvic health, pain with sex, evidence-based therapies for low desire and arousal, how contraception and medications can affect sexual function, and practical strategies for enhancing sexual satisfaction and maintaining intimacy across life stages. This episode offers a comprehensive, evidence-based discussion with immediate real-world relevance for women as well as for men who want to better understand their partners.

We discuss:

How sexual health influences physical health, emotional well-being, and relationships [3:15];

Understanding the physiology of the female orgasm, sexual comfort and satisfaction, and the disparity between men and women [12:45];

Foreplay, the science of desire, and methods to help women cultivate arousal and connection [19:00];

The physiology and sources of female lubrication, the role of clitoral nerve anatomy in pleasure, and the use of lubricants and vibrators to enhance comfort and sexual health [23:45];

Understanding female anatomy and what is needed for orgasm [31:15];

Understanding sexual desire, how to cultivate it, the role of hormones, and testosterone therapy in women [41:15];

Personalizing perimenopause care: how desire for ovulation guides the choice between contraception and menopausal hormone therapy [49:30];

Considerations for choosing contraceptives and hormonal therapies during perimen…
Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast)

27 oktober 2025 · 1 uur 25 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity.

We discuss:

Key points about starting exercise as an older adult [2:45];

Overview of episode topics and structure [1:45];

How Peter defines longevity [3:45];

Why healthspan is a crucial component of longevity [11:15];

The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30];

Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00];

Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15];

Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30];

The spectrum of metabolic diseases [43:15];

Why it's never too late to start thinking about longevity [44:15];

The 5 components of the longevity toolkit [46:30];

Peter's framework for exercise—The Centenarian Decathlon [47:45];

Peter's nutritional framework: energy balance, protein intake, and more [58:45];

Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30];

Drugs and supplements: Peter's framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30];

Why emotional health is a key component of longevi…
#370 - AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?

27 oktober 2025 · 17 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this "Ask Me Anything" (AMA) episode, Peter revisits the "proven, promising, fuzzy, noise, nonsense" scale and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility.

If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #76 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

A scale for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense [1:30];

Strong convictions, loosely held: the mindset that separates great scientists from the rest [7:30];

GLP-1 receptor agonists: are there benefits beyond improving metabolic health and promoting weight loss? [12:45];

GLP-1 drugs and the brain: exploring the potential cognitive benefits [18:45];

GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects [23:00];

Rapamycin and geroprotection: why it remains in the "promising" category [25:45];

SGLT2 inhibitors and their potential geroprotective effect [27:30];

Methylene blue: examinin…
#369 ‒ Rethinking protein needs for performance, muscle preservation, and longevity, and the mental and physical benefits of creatine supplementation and sauna use | Rhonda Patrick, Ph.D.

20 oktober 2025 · 1 uur 50 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Rhonda Patrick is a scientist, health educator, and host of the FoundMyFitness podcast whose work explores the intersection of nutrition, aging, and disease prevention. In this episode, Rhonda joins Peter for part two of his deep dive on protein, continuing last week's discussion with David Allison and expanding the conversation to include creatine supplementation and sauna use. She discusses why the current RDA for protein is insufficient, how much more is needed to maintain muscle mass and prevent frailty, how activity level and aging influence protein requirements through mechanisms such as anabolic resistance, and how to determine optimal protein intake. The conversation also covers creatine's proven effects on strength, endurance, and performance; its overlooked benefits for cognition and brain health; and the optimal dosing for different populations. Rhonda closes with the science behind sauna use, including its cardiovascular and cognitive benefits, the role of heat shock proteins, and practical guidance on temperature and duration.

We discuss:

Why the current protein RDA is too low, and why maintaining sufficient amino acid intake is vital for muscle preservation and health [3:30];

The case for raising the protein RDA by at least 50% [9:45];

Anabolic resistance: why inactivity—more than aging—blunts the body's response to protein, and how resistance training restores it [14:00];

How sarcopenia develops, the profound effect of frailty on quality of life, and why it's crucial to build and maintain muscle early [20:00];

Finding the optimal protein dose [25:00];

Why aiming higher is smarter: the case for targeting 2g of protein per kg of body weight in the real world [32:15];

Protein needs for pregnant women and growing adolescents [37:30];

Why higher protein intake is crucial when trying to lose fat while preserving or…
#368 ‒ The protein debate: optimal intake, limitations of the RDA, whether high-protein intake is harmful, and how to think about processed foods | David Allison, Ph.D.

13 oktober 2025 · 1 uur 49 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

David Allison is a world-renowned scientist and award-winning scientific writer who has spent more than two decades at the forefront of obesity research. In this episode, David joins for his third appearance on The Drive to bring clarity to one of the most contentious topics in modern nutrition—protein. He explores the historical pattern of demonizing macronutrients, the origins and limitations of the RDA for protein, and what the evidence really says about higher protein intake, muscle protein synthesis, and whether concerns about harm are supported by actual data. He also discusses the challenges of conducting rigorous nutrition studies, including the limits of epidemiology and crossover designs, as well as conflicts of interest in nutrition science and why transparency around data, methods, and logic matter more than funding sources. The episode closes with a discussion on processed and ultra-processed foods, the public health challenges of tackling obesity, and whether future solutions may depend more on drugs like GLP-1 agonists or broader societal changes. This is part one of a two-part deep dive on protein, setting the stage for next week's conversation with Rhonda Patrick.

We discuss:

The cyclical pattern of demonizing different macronutrients in nutrition and why protein has recently become the latest target of controversy [3:15];

The origin and limits of the protein RDA: from survival thresholds to modern optimization [6:30];

Trust vs. trustworthiness: why data, methods, and logic matter more than motives in science [13:30];

The challenges of nutrition science: methodological limits, emotional bias, and the path to honest progress [17:15];

Why the protein RDA is largely inadequate for most people, and the lack of human evidence that high protein intake is harmful [30:30];

Understanding the dose-response curve for mu…
#367 - Tylenol, pregnancy, and autism: What recent studies show and how to interpret the data

6 oktober 2025 · 1 uur 27 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

In this special episode of The Drive, Peter addresses the recent headlines linking acetaminophen (Tylenol) use during pregnancy to autism in exposed children. Recognizing the confusion these claims have sparked among patients, listeners, and the broader public, Peter uses this episode to provide a framework for thinking critically about complex conditions and the research related to them. He highlights the dramatic rise in autism diagnoses over recent decades, noting that multifactorial conditions rarely have a single cause, and emphasizes the importance of resisting oversimplified explanations. Peter also stresses that humans are not naturally wired for scientific thinking, making disciplined frameworks like the Bradford Hill criteria essential for evaluating causality in epidemiology. Ultimately, he uses this framework to explore the evidence surrounding acetaminophen use during pregnancy and its potential link to autism.

We discuss:

Laying the groundwork for this discussion, the rise in autism rates, and the value in using frameworks [1:00];

The FDA pregnancy drug categories, where Tylenol falls within that framework, and a structured method for evaluating scientific evidence and causality [6:00];

What exactly are the claims being made about acetaminophen and autism? [13:45];

The increase in autism rates and why so many things are being linked to autism: the multiple comparisons problem [15:00];

Evaluating the review paper that triggered the recent concern over acetaminophen and autism [21:45];

Breaking down the largest studies on prenatal Tylenol exposure and autism: is there a causal link? [35:00];

Why observational studies can't prove causality, the role of confounding variables, and the importance of frameworks like the Bradford Hill criteria [43:30];

Applying the Bradford Hill criteria: testing the case for Tylenol …
#366 ‒ Transforming education with AI and an individualized, mastery-based education model | Joe Liemandt

29 september 2025 · 1 uur 47 min
Afspelen

View the Show Notes Page for This Episode Lees meer

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter's Weekly Newsletter

Joe Liemandt is a software entrepreneur turned education reformer who left Stanford in 1989 to found Trilogy, a highly profitable private software company, before pivoting to transforming K-12 learning. In this episode, Joe shares how he transitioned from leading a global software enterprise to becoming principal of Alpha School, where his focus is building a mastery-based, individualized education model that leverages AI as the missing infrastructure for large-scale change. He details the shortcomings of traditional K-12 education, explains how Alpha replaces conventional seat time with focused academics, and outlines the role of AI tutors and human coaches in helping students accelerate through material. Joe also discusses early results, the data-driven systems that track progress, and his ambitious plan to reach a billion children in the next 20 years by combining cutting-edge technology with proven learning science.

We discuss:

Joe's early interest in AI and the story of how he quit school to build Trilogy [4:45];

Joe's first encounter with Alpha School and how it sparked his journey into education innovation [8:15];

America's declining K-12 performance and the hidden power of mastering fundamentals [13:00];

How traditional time-based grade progression undermines later learning, and how mastery-focused instruction can transform student achievement [20:30];

Motivation as the key to high-level learning: how Alpha School fosters motivation with its "Timeback" model and leverages AI to accelerate learning [28:45];

Core principles of learning: how high standards, mastery-based instruction, and supportive struggle foster both academic excellence and personal growth [35:45];

Breaking down self-imposed limitations with foundational skills, defined time requirements, and a mastery model [41:15];

Using short-term extrinsic reward…

Alle afleveringen

#413 ‒ The neuroscience of emotion: challenging conventional theories of emotion, how the brain predicts and constructs our experiences, and gaining greater control over how we feel | Lisa Feldman Barrett, Ph.D.

#412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, and the advances reshaping treatment | Siddhartha Mukherjee, M.D., Ph.D.

#411 ‒ AMA #90: Strong convictions, loosely held: how Peter's views on fasting, keto, metformin, rapamycin, whole-body MRI, and exercise have changed

#410 ‒ The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | Kathryn Gray, M.D., Ph.D.

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

#403 ‒ Peptides: separating scientific promise from marketing hype

#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.

#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results

#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy

#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration

#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit

#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.

#379 - AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence

#378 ‒ Women's health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D.

Building & Changing Habits | James Clear (#183 rebroadcast)

#377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur Brooks

#376 - AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more

#375 - Ketogenic diet, ketosis & hyperbaric oxygen: metabolic therapies for weight loss, cognition, Alzheimer's & more | Dom D'Agostino, Ph.D.

#374 - The evolutionary biology of testosterone: how it shapes male development and sex-based behavioral differences, | Carole Hooven, Ph.D.

The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast)

#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

#372 - AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications

#371 – Women's sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H.

Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast)

#370 - AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?

#369 ‒ Rethinking protein needs for performance, muscle preservation, and longevity, and the mental and physical benefits of creatine supplementation and sauna use | Rhonda Patrick, Ph.D.

#368 ‒ The protein debate: optimal intake, limitations of the RDA, whether high-protein intake is harmful, and how to think about processed foods | David Allison, Ph.D.

#367 - Tylenol, pregnancy, and autism: What recent studies show and how to interpret the data

#366 ‒ Transforming education with AI and an individualized, mastery-based education model | Joe Liemandt